Cancer Treatment Centers of America Selects WIRB-Copernicus Group
WIRB-Copernicus Group announced that it has been chosen by Cancer Treatment Centers of America to expand its clinical research program.
WIRB-Copernicus Group (WCG), a global provider of regulatory and ethical review services and software to support clinical research, announced that it has been chosen by Cancer Treatment Centers of America® (CTCA) to expand its clinical research program. WCG will assist CTCA in the centralization and optimization of its regulatory and ethical review process, allowing CTCA to manage a higher volume of cutting-edge research while maintaining participant protection. CTCA is a leader in integrative cancer care with a national network of five state-of-the-art hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.WCG was chosen for its experience in reviewing oncology research, and WCG Oncology™, WCG’s oncology-focused oversight division, will partner with CTCA in its expansion process.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
